(Total Views: 467)
Posted On: 12/29/2018 8:09:09 PM
Post# of 30067
.jpg)
1/2 We maintain control over our only Phase 3 asset, ESS in Cutanogen Corp. We are selling our Phase 2b asset Eltoprazine to Coeptis Pharma, who is now completing a pre-IPO round ahead of a planned IPO within 12 months of the closing of the transaction.
2/2 We have JV’ed our LymPro asset with Todos $TOMDF for a significant equity stake, and are evaluating options for MANF. We expect the sum of the parts far outweigh our market cap and our enterprise value. The spin-off strategy implemented to reduce parent capital requirements
G's Tweets last night in response to some twitter criticism, for all of you lacking twitter
2/2 We have JV’ed our LymPro asset with Todos $TOMDF for a significant equity stake, and are evaluating options for MANF. We expect the sum of the parts far outweigh our market cap and our enterprise value. The spin-off strategy implemented to reduce parent capital requirements
G's Tweets last night in response to some twitter criticism, for all of you lacking twitter
(5)
(0)
